The Phase IIa results continue a surge of momentum in a treatment space that last week saw the approval of Vertex’s Journavx ...

A dysfunctional signaling pathway in the hippocampus has been linked to chronic pain-related memory impairment in mice.

The three pathways were given in random order: The trial completed recruitment in 2020 ... Our study can influence future treatment guidelines for DPNP, but also chronic neuropathic pain treatment in ...

Explore how chemotherapy causes peripheral neuropathy in 40% of cancer patients. Learn about the risk factors and the need ...

Unfortunately, current pharmacological treatments for neuropathic pain lack clinical efficacy and often lead to harmful adverse reactions. As G protein-coupled receptors (GPCRs) are widely distributed ...

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...

The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...

Worldwide, cancer chemotherapy is linked to persistent severe peripheral nerve pain (neuropathy) for around 4 in every 10 patients treated with these drugs, suggests a pooled data analysis of the ...

R esearchers at the NYU Pain Research Center have found a new receptor for nerve growth factor that plays an important role in pain signaling, even though it does not signal on its own, according ...

“The pain was unbearable ... I had to create those neuropathic pathways again. It was a slow process but my physios, gym trainers and psychologist were all there to support me,” she recalls.